AAAAAA

   
Results: 1-9 |
Results: 9
THE EFFECT OF TOLCAPONE ON LEVODOPA PHARMACOKINETICS IS INDEPENDENT OF LEVODOPA CARBIDOPA FORMULATION/
Authors: JORGA K FOTTELER B SEDEK G NIELSEN T AITKEN J
Citation: K. Jorga et al., THE EFFECT OF TOLCAPONE ON LEVODOPA PHARMACOKINETICS IS INDEPENDENT OF LEVODOPA CARBIDOPA FORMULATION/, Journal of neurology, 245(4), 1998, pp. 223-230
EFFECT OF TOLCAPONE ON PLASMA LEVODOPA CONCENTRATIONS AFTER COADMINISTRATION WITH LEVODOPA CARBIDOPA TO HEALTHY-VOLUNTEERS/
Authors: SEDEK G JORGA K SCHMITT M BURNS RS LEESE P
Citation: G. Sedek et al., EFFECT OF TOLCAPONE ON PLASMA LEVODOPA CONCENTRATIONS AFTER COADMINISTRATION WITH LEVODOPA CARBIDOPA TO HEALTHY-VOLUNTEERS/, Clinical neuropharmacology, 20(6), 1997, pp. 531-541
PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE DOSES OFTHE MAO-B INHIBITOR LAZABEMIDE IN HEALTHY-SUBJECTS
Authors: DINGEMANSE J WOOD N JORGA K KETTLER R
Citation: J. Dingemanse et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE DOSES OFTHE MAO-B INHIBITOR LAZABEMIDE IN HEALTHY-SUBJECTS, British journal of clinical pharmacology, 43(1), 1997, pp. 41-47
EFFECT OF THE COMT INHIBITOR TOLCAPONE ON THE HEMODYNAMIC-EFFECTS ANDTOLERABILITY OF THE COMBINATION TREATMENT WITH LEVODOPA CARBIDOPA ANDDESIPRAMINE IN HEALTHY-VOLUNTEERS/
Authors: JORGA K FOTTELER B SEDEK G MODI M RABBIA M
Citation: K. Jorga et al., EFFECT OF THE COMT INHIBITOR TOLCAPONE ON THE HEMODYNAMIC-EFFECTS ANDTOLERABILITY OF THE COMBINATION TREATMENT WITH LEVODOPA CARBIDOPA ANDDESIPRAMINE IN HEALTHY-VOLUNTEERS/, Neurology, 48(3), 1997, pp. 3103-3103
THE EFFECT OF COMT INHIBITION BY TOLCAPONE ON TOLERABILITY AND PHARMACOKINETICS OF DIFFERENT LEVODOPA BENSERAZIDE FORMULATIONS/
Authors: JORGA K FOTTELER B SCHMITT M NIELSEN T ZURCHER G AITKEN J
Citation: K. Jorga et al., THE EFFECT OF COMT INHIBITION BY TOLCAPONE ON TOLERABILITY AND PHARMACOKINETICS OF DIFFERENT LEVODOPA BENSERAZIDE FORMULATIONS/, European neurology, 38(1), 1997, pp. 59-67
WHY SHOULD TOLCAPONE BE GIVEN AT A LOWER DOSE TO PATIENTS WITH LIVER-CIRRHOSIS
Authors: JORGA K FOTTELER B VANBRUMMELEN P
Citation: K. Jorga et al., WHY SHOULD TOLCAPONE BE GIVEN AT A LOWER DOSE TO PATIENTS WITH LIVER-CIRRHOSIS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 73-73
MULTIPLE-DOSE CLINICAL-PHARMACOLOGY OF THE CATECHOL-O-METHYL-TRANSFERASE INHIBITOR TOLCAPONE IN ELDERLY SUBJECTS
Authors: DINGEMANSE J JORGA K ZURCHER G FOTTELER B SEDEK G NIELSEN T VANBRUMMELEN P
Citation: J. Dingemanse et al., MULTIPLE-DOSE CLINICAL-PHARMACOLOGY OF THE CATECHOL-O-METHYL-TRANSFERASE INHIBITOR TOLCAPONE IN ELDERLY SUBJECTS, European Journal of Clinical Pharmacology, 50(1-2), 1996, pp. 47-55
LACK OF INTERACTION BETWEEN EPHEDRINE AND COMBINATION OF TOLCAPONE AND SINEMET
Authors: SEDEK G JORGA K YOO K HOOD J
Citation: G. Sedek et al., LACK OF INTERACTION BETWEEN EPHEDRINE AND COMBINATION OF TOLCAPONE AND SINEMET, Neurology, 46(2), 1996, pp. 5120-5120
PHARMACOKINETIC-PHARMACODYNAMIC INTERACTION BETWEEN THE COMT INHIBITOR TOLCAPONE AND SINGLE-DOSE LEVODOPA
Authors: DINGEMANSE J JORGA K ZURCHER G SCHMITT M SEDEK G DAPRADA M VANBRUMMELEN P
Citation: J. Dingemanse et al., PHARMACOKINETIC-PHARMACODYNAMIC INTERACTION BETWEEN THE COMT INHIBITOR TOLCAPONE AND SINGLE-DOSE LEVODOPA, British journal of clinical pharmacology, 40(3), 1995, pp. 253-262
Risultati: 1-9 |